Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | KHK | P50053 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26987219 | 0.81 | HRH4 (0.59) | GAAMAPTSMN1; SMN2KDM4EGFER | |
| SCHEMBL26427544 | 0.81 | CHRNA7 (0.47) | RAD52GAACHRNA7MAPTSMN1; SMN2 | |
| SCHEMBL2594167 | 0.81 | RAD52 (0.56) | RAD52GAACHRNA7MAPTSMN1; SMN2 | |
| SCHEMBL1634508 | 0.79 | CHKA (0.52) | GAAMAPTHTTALDH1A1HRH4 | |
| SCHEMBL30900615 | 0.79 | CHKA (0.52) | GAAMAPTHTTALDH1A1HRH4 | |
| SCHEMBL25247515 | 0.79 | HRH4 (0.47) | HRH4RXRAGRIN1GRIN2B | |
| SCHEMBL22601526 | 0.78 | CHRNA7 (0.47) | RAD52GAACHRNA7MAPTSMN1; SMN2 | |
| SCHEMBL31341814 | 0.78 | HRH4 (0.54) | GAAMAPTKDM4EHTTALDH1A1 | |
| SCHEMBL5314278 | 0.78 | HRH4 (0.54) | GAAMAPTKDM4EHTTALDH1A1 | |
| SCHEMBL5253497 | 0.77 | ALDH1A1 (0.49) | MAPTSMN1; SMN2KDM4EGFERALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089608-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | RAD52 1412/4885GAA 1351/4885CHRNA7 4310/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | RAD52 1412/4885GAA 1351/4885CHRNA7 4310/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | RAD52 1412/4885GAA 1351/4885CHRNA7 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.